Chardan, a global investment bank, announced today that the firm acted as sole placement agent in Krystal Biotech, Inc.’s securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at $16 per share. The private placement will yield gross proceeds of $10 million.
“We’re pleased to have partnered with Krystal Biotech to support the firm’s efforts to continue its impressive research in dermatological diseases,” said Jonas Grossman, President of Chardan. “Our experience in the space allowed us to find the capital needed to support this growth and we’re looking forward to working with the team at Krystal to support future advancements.”
Chardan has participated in advisory and capital raising transactions totaling more than $2 billion in 2018.
Date: September 24, 2018
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Cision
